HLA-DM can partially replace the invariant chain for HLA-DR transport and surface expression in transfected endocrine epithelial cells

Tissue Antigens

Volumn 53, Issue 5, 1999, Pages 447-458

  Serradell, L ^a   Muntasell, A ^a   Catalfamo M ^a   Marti M ^a   Costa, M ^a   De Preval C ^b   Jaraquemada, D ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b Inst Natl de la Sante et de la R   (France)

Author keywords

Autoimmunity; Class II molecules; Endocrine epithelial cells; HLA DM; Intracellular transport; Invariant chain

Indexed keywords

CD4 ANTIGEN; COMPLEMENTARY DNA; DODECYL SULFATE SODIUM; HLA ANTIGEN CLASS 2; HLA D ANTIGEN; HLA DR ANTIGEN; MESSENGER RNA;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; ENDOCRINE CELL; ENDOPLASMIC RETICULUM; EPITHELIUM CELL; FLOW CYTOMETRY; GENETIC TRANSFECTION; HISTOCHEMISTRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IMMUNOPRECIPITATION; INSULINOMA; NORTHERN BLOTTING; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN LOCALIZATION; T LYMPHOCYTE;

ANIMALS; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; BIOLOGICAL TRANSPORT; CELL MEMBRANE; DIMERIZATION; ENDOCRINE GLANDS; ENDOPLASMIC RETICULUM; EPITHELIAL CELLS; GENE EXPRESSION; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-D ANTIGENS; HLA-DR3 ANTIGEN; HLA-DR4 ANTIGEN; HUMANS; RATS; SODIUM DODECYL SULFATE; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0032923690     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0039.1999.530501.x     Document Type: Article

References (59)

1. 1. Roche PA, Marks M, Cresswell P. Formation of a nine-subunit complex by HLA class II glycoproteins and the invariant chain. Nature 1991: 354: 392-1.
2. 2. Long EO, LaVaute T, Pinet V, Jaraquemada D. Invariant chain prevents the HLA-DR-restricted presentation of cytosolic peptide. J Immunol 1994: 153: 1487-94.
3. 3. Bakke O, Dobberstein B. MHC class II-associated invariant chain contains a sorting signal for endosomal compartments. Cell 1990: 63: 707-16.
4. 4. Lotteau V, Teyton L, Peleraux A et al. Intracellular transport of class II MHC molecules directed by invariant chain. Nature 1990: 348: 600-5.
5. 5. Maric MA, Taylor MD, Blum JS. Endosomal aspartic proteinases are required for invariant chain processing. Proc Natl Acad Sci U S A 1994: 91: 2171-5.
6. 6. Avva RR, Cresswell P. In vivo and in vitro formation and dissociation of HLA-DR complexes with invariant chain-derived peptides. Immunity 1994: 1: 763-74.
7. 7. Green JM, Pierce SK. Class II antigen processing compartments and function of HLA-DM. Inter Rev Immunol 1996: 13: 209-19.
8. 8. Mosyak L, Zaller DM, Wiley DC. The structure of HLA-DM, the peptide exchange catalyst that loads antigen onto class II MHC molecules during antigen presentation. Immunity 1998: 9: 377-83.
9. 9. Denzin LK, Cresswell P. HLA-DM induces CLIP dissociation from HLA class II αβ dimers and facilitates peptide loading. Cell 1995: 82: 155-65.
10. 10. Sloan VS, Cameron P, Porter G et al. Mediation by HLA-DM of dissociation of peptides from HLA-DR. Nature 1995: 375: 802-6.
11. 11. Kropshofer H, Arndt SO, Moldenhauer G, Hämmerling GJ, Vogt AB. HLA-DM acts as a molecular chaperone and rescues empty HLA-DR molecules at lysosomal pH. Immunity 1997: 6: 293-302.
12. 12. Viville S, Neefjes JJ, Lotteau V et al. Mice lacking the MHC class II-associated invariant chain. Cell 1993: 72: 635-48.
13. + T-cell selection in mice lacking invariant chain expression. J Exp Med 1993: 177: 1699-712.
14. 14. Miyazaki T, Wolf P, Tourne S et al. Mice lacking H2-M complexes, enigmatic elements of the MHC class II peptide loading pathway. Cell 1996: 84: 531-41.
15. 15. Schafer PH, Grenn JM, Malapati S, Gu L, Pierce S. HLA-DM is present in one-fifth the amount of HLA-DR in the class II peptide-loading compartment where it associates with leupeptin-induced peptide (LIP)-HLA-DR complexes. J Immunol 1996: 157: 5487-95.
16. 16. Hanafusa T, Pujol-Borrell R, Chiovato L, Russel RCG, Doniach D, Bottazzo GF. Aberrant expression of HLA-DR antigen on thyrocytes in Graves' disease: relevance in autoimmunity. Lancet 1983: 2: 1111-5.
17. 17. Catálfamo M, Serradell L, Roura-Mir C et al. HLA-DM and invariant chain are expressed by thyroid follicular cells, enabling the expression of compact DR molecules. Int Immunol 1999: 11: 269-77.
18. 18. Somoza N, Vargas F, Roura-Mir C et al. Pancreas in recent onset insulin-dependent diabetes mellitus. Changes in HLA, adhesion molecules and autoantigens, restricted T cell, receptor Vb usage, and cytokine profiles. J Immunol 1994: 153: 1360-77.
19. 19. Vidal K, Samarut C, Magaud JP, Revillard JP, Kaiserlian D. Unexpected lack of reactivity of allogeneic anti-Ia monoclonal antibodies with MHC class II molecules expressed by mouse intestinal epithelial cells. J Immunol 1993: 151: 4642-50.
20. 20. Gazdar AF, Chick WL, Oie HK et al. Continuous clonal insulin and somatostatin secreting cell lines established from a transplantable rat islet cell tumor. Proc Natl Acad Sci U S A 1980: 77: 3523-6.
21. 21. Baekkeskov S, Aanstoot HJ, Christgau S et al. Identification of the 64k autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 1990: 347: 151-6.
22. 22. Roep BO, Arden SS, de Vries RR, Hutton JC. T-cell clones from type-I diabetes patient respond to insulin secretory granule proteins. Nature 1990: 345: 632-4.
23. 23. Castaño L, Russo E, Zhou L, Lipes MA, Eisenbarth G. Identification and cloning of a granule autoantigen (carboxypeptidase-H) associated with type I diabetes. J Clin Endocrinol Metab 1991: 73: 1197-1201.
24. 24. Van Vliet E, Roep BO, Meulenbroek L, Bruining J, de Vries RR. Human T cell clones with specificity for insulinoma cell antigens. Eur J Immunol 1989: 19: 213-6.
25. 25. Roep BO, Kallan AA, Hazenbos WL et al. T-cell reactivity to 38 kD insulin-secretory granule protein in patients with recent-onset type I diabetes. Lancet 1991: 337: 1439-41.
26. 26. Thorsby E. 1997. HLA associated diseases. A summary of the 12th international histocompatibility workshop component. In: Charron D, ed. Genetic diversity of HLA. Functional and Medical Implications. Vol II. Paris: EDK, 1997: 91.
27. 27. Lampson LA, Levy R. Two populations of Ia-like molecules on a human B cell line. J Immunol 1980: 125: 293-9.
28. 28. Koning F, Schreuder GMT, Giphart MJ, Bruning JW. A mouse monoclonal antibody detecting a DR-related MT2-like specificity: serology and biochemistry. Hum Immunol 1984: 9: 221-30.
29. 29. Quaranta V, Madjic O, Stingl G, Liszka K, Honigsmann H, Knapp W. A human Ia cytoplasmic determinant located on multiple forms of invariant chain (gamma, gamma 2, gamma 3). J Immunol 1984: 132: 1900-5.
30. 30. Denzin LK, Robbins NF, Carboy-Newcomb C, Cresswell P. Assembly and intracellular transport of HLA-DM and correction of the class II antigen-processing defect in T2 cells. Immunity 1994: 1: 595-606.
31. 31. Sherman MA, Weber DA, Jensen PE. DM enhances peptide binding to class II MHC by release of invariant chain derived peptide. Immunity 1995: 3: 197-203.
32. 32. Long EO, Rosen-Bronson S, Karp DR, Manalti MS, Sékaly RP, Jaraquemada D. Efficient cDNA expression vectors for stable and transient expression of HLA-DR in transfected fibroblast and lymphoid cells. Hum Immunol 1991: 31: 229-35.
33. 33. Roche PA, Teletski CL, Karp DR, Pinet V, Bakke O, Long EO. Stable surface expression of invariant chain prevents peptide presentation by HLA-DR. EMBO J 1992: 11: 2841-7.
34. 34. Chomczynsky P, Sacchi N. Single step of RNA isolation by acid guanidium thiocianate-phenol-chloroform extraction. Anal Biochem 1987: 162: 156-9.
35. 35. Lightstone L, Hargreaves R, Bobek G et al. In the absence of the invariant chain, HLA-DR molecules display a distinct array of peptides which is influenced by the presence or absence of HLA-DM. Proc Natl Acad Sci U S A 1997: 94: 5772-7.
36. 36. Germain RN, Hendrix LR. MHC class II structure, occupancy and surface expression determined by post-endoplasmic reticulum antigen binding. Nature 1991: 369: 134-9.
37. 37. Shackelford DA, Strominger JL. Analysis of the oligosaccharides on the HLA-DR and DC1 B cell antigens. J Immunol 1983: 130: 274-83.
38. 38. Sanderson F, Thomas C, Neefjes J, Trowsdale J. Association between HLA-DM and HLA-DR in vivo. Immunity 1996: 4: 87-96.
39. 39. Neefjes JJ, Ploegh HL. Inhibition of endosomal proteolytic activity by leupeptin blocks surface expression of MHC class II molecules and their conversion to SDS resistant αβ heterodimers in endosomes. EMBO J 1992: 11: 411-6.
40. 40. Pinet V.M, Long EO. Peptide loading onto recycling HLA-DR molecules occurs in early endosomes. Eur J Immunol 1998: 28: 799-804.
41. 41. Schaiff WT, Hruska KA Jr, McCourt DW, Green M, Schwartz BD. HLA-DR associates with specific stress proteins and is retained in the endoplasmic reticulum in invariant chain negative cells. J Exp Med 1992: 176: 657-66.
42. 42. Busch R, Cloutier I, Sékaly RP, Hämmerling GJ. Invariant chain protects class II histocompatibility antigens from binding intact polypeptides in the endoplasmic reticulum. EMBO J 1996: 15: 418-28.
43. 43. Tan LJ, Ceman S, Chervonsky A, Rodriguez-Paris J, Steck TL, Sant AJ. Late events in the intracellular sorting of major histocompatibility complex class II molecules are regulated by the 80-82 segment of the class II β chain. Eur J Immunol 1997: 27: 1479-88.
44. 44. Marks MS, Roche PA, Van Donselaar E, Woodruff L, Peters PJ, Bonifacino JS. A lysosomal targeting signal in the cytoplasmic tail of the β chain directs HLA-DM to MHC class II compartments. J Cell Biol 1995: 131: 351-69.
45. 45. Ulrich HJ, Döring K, Grüneberg V et al. Interaction between HLA-DM and HLA-DR involves regions that undergo conformational changes at lysosomal pH. Proc Natl Acad Sci U S A 1997: 94: 13163-68.
46. 46. Guerra CB, Busch R, Doebele RC et al. Novel Glycosilation of HLA-DRα Disrupts Antigen Presentation without Altering Endosomal Localization. J Immunol 1998: 160: 4289-97.
47. 47. Liljedahl M, Kuwana T, Fung-Leung WP, Jackson MR, Peterson PA, Karlsson L. HLA-DO is a lysosomal resident which requires association with HLA-DM for efficient intracellular transport. EMBO J 1996: 15: 4817-24.
48. 48. Copier J, Potter P, Sacks SH, Kelly AP. Multiple signals regulate the intracellular trafficking of HLA-DM in B lymphoblastoid cells. Immunology 1998: 93: 505-10.
49. 49. Katz JF, Stebbins C, Appella E, Sant AJ. Invariant chain and DM edit self-peptide presentation by major histocompatibility complex (MHC) class II molecules. J Exp Med 1996: 184: 1747-53.
50. 50. Tourne S, Miyazaki T, Wolf P, Ploegh H, Benoist C, Mathis D. Functionality of major histocompatibility complex class II molecules in mice doubly deficient for invariant chain and H2-M complexes. Proc Natl Acad Sci U S A 1997: 94: 9255-60.
51. 51. Kenty G, Martin WD, Van Kaer L et al. MHC class II expression in double mutant mice lacking Invariant chain and DM functions. J Immunol 1998: 160: 606-14.
52. 52. Mellman I. Endocytosis and molecular sorting. Annu Rev Cell Dev Biol 1996: 12: 575-625.
53. 53. Sette A, Ceman S, Kubo RT et al. Invariant chain peptides in mast HLA-DR molecules of an antigen-processing mutant. Science 1992: 258: 1801-4.
54. 54. Riberdy JM, Newcomb JR, Surman MJ, Barbosa JA, Cresswell P. HLA-DR molecules from an antigen-processing mutant-cell line are associated with invariant chain. Nature 1992: 360: 474-7.
55. 55. Cresswell P. Assembly, transport and function of MHC class II molecules. Ann Rev Immunol 1994: 12: 259-93.
56. 56. Chicz RM, Urban RG, Lane WS et al. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogenous in size. Nature 1992: 358: 764-8.
57. 57. Douek DC, Altmann DM. HLA-DO is an intracellular class II molecule with distinctive thymic expression. Int Immunol 1997: 9: 355-64.
58. 58. Denzin LK, Sant'Angelo DB, Hammond C, Surman MJ, Cresswell P. Negative regulation by HLA-DO of MHC class II-restricted antigen processing. Science 1997: 278: 106-9.
59. 59. Kovats S, Grubin CE, Eastman S et al. Invariant chain-independent function of H-2M in the formation of endogenous peptide-major histocompatibility complex class II complexes in vivo. J Exp Med 1998: 187: 245-5 1.